Lipid-bilayer-coated nanogels allow for sustained release and enhanced internalization

Qin, Chao; Lv, Yaqi; Xu, Chaoran; Li, Jingjing; Yin, Lifang; He, Wei

doi:10.1016/j.ijpharm.2018.09.008

Cited by 19 publications

(11 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although PTX‐Ns‐induced apoptosis with higher efficacy compared with free PTX, however, this nanomedicine exhibited lower cytotoxicity at high concentrations. Our previous reports also displayed similar results . Furthermore, combined use with other drugs, such as gene and protein, made this enhancement more profound .…”

Section: Discussionsupporting

confidence: 72%

“…Our previous reports also displayed similar results. [54][55][56] Furthermore, combined use with other drugs, such as gene and protein, made this enhancement more profound. 54,55 The previous report indicated that internalized PTX-Ns started to dissolve at 10 hr postinternalization, and therefore demonstrating sustained PTX release over time in cells.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

“Locked” cancer cells are more sensitive to chemotherapy

Lyu

Xiao

et al. 2019

Bioengineering & Transla Med

Self Cite

View full text Add to dashboard Cite

The treatment of metastatic cancer is a great challenging issue throughout the world. Conventional chemotherapy can kill the cancer cells and, whereas, would exacerbate the metastasis and induce drug resistance. Here, a new combinatorial treatment strategy of metastatic cancer was probed via subsequentially dosing dual nanomedicines, marimastat‐loaded thermosensitive liposomes (MATT‐LTSLs) and paclitaxel nanocrystals (PTX‐Ns), via intravenous and intratumoral injection. First, the metastasis was blocked and cancer cells were locked in the tumor microenvironment (TME) by delivering the matrix metalloproteinase (MMP) inhibitor, MATT, to the tumor with LTSLs, downregulating the MMPs by threefold and reducing the degradation of the extracellular matrix. And then, the “locked” cancer cells were efficiently killed via intratumoral injection of the other cytotoxic nanomedicine, PTX‐Ns, along with no metastasis and 100% inhibition of tumor growth. This work highlights the importance of the TME's integrity in the chemotherapy duration. We believe this is a generalized strategy for cancer treatment and has potential guidance for the clinical administration.

show abstract

Section: Discussionsupporting

confidence: 72%

Section: Discussionmentioning

confidence: 99%

“Locked” cancer cells are more sensitive to chemotherapy

Lyu

Xiao

et al. 2019

Bioengineering & Transla Med

Self Cite

View full text Add to dashboard Cite

show abstract

“…( 2017 ) prepared liposome-templated hydrogel nanoparticles (LHNPs) for the codelivery of Cas9 protein and nucleic acids to fulfill a gene silencing function of the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated protein 9 (Cas9) technology. Trastuzumab (Tmab), as an antibody targeting human epidermal growth factor receptor 2 (HER2), was combined with LP–Gel hybrids to tackle breast cancer (Qin et al., 2018 ). In addition, neoantigen peptides, together with black phosphorus quantum dots, and immune adjuvants were incorporated into two compartments of LP–Gel to achieve photothermal immunotherapy (Zhang et al., 2020 ).…”

Section: Preparation Of Lp–gelmentioning

confidence: 99%

“…For the lipid-coated hydrogel type, the hydrogel core can reduce the deformability of lipid bilayers and the resultant membrane fluidity, thereby promoting cellular uptake of drugs to enhance the cytotoxicity of chemotherapeutic drugs to cancer cells (Qin et al., 2018 ). Besides, the hydrogel core can respond to external stimuli and either swells or shrinks in a reversible and controllable process, finally resulting in mechanical squeezing of the loaded drug (De Geest et al., 2006 ; Krebs & Alsberg, 2011 ).…”

Section: Design Principles Of Lp–gelmentioning

confidence: 99%

“…In conclusion, lipobeads maintain the advantages of liposomal drug carriers while additionally providing stronger mechanical support with better stimuli responsiveness. Furthermore, the increased stiffness conferred by complexation of the microgel greatly enhanced the cellular uptake of the lipobeads (Qin et al., 2018 ).…”

Section: Applications For Anticancer Therapymentioning

confidence: 99%

See 1 more Smart Citation

Design and applications of liposome-in-gel as carriers for cancer therapy

et al. 2022

View full text Add to dashboard Cite

Cancer has long been a hot research topic, and recent years have witnessed the incidence of cancer trending toward younger individuals with great socioeconomic burden. Even with surgery, therapeutic agents serve as the mainstay to combat cancer in the clinic. Intensive research on nanomaterials can overcome the shortcomings of conventional drug delivery approaches, such as the lack of selectivity for targeted regions, poor stability against degradation, and uncontrolled drug release behavior. Over the years, different types of drug carriers have been developed for cancer therapy. One of these is liposome-in-gel (LP–Gel), which has combined the merits of both liposomes and hydrogels, and has emerged as a versatile carrier for cancer therapy. LP–Gel hybrids have addressed the lack of stability of conventional liposomes against pH and ionic strength while displaying higher efficiency of delivery hydrophilic drugs as compared to conventional gels. They can be classified into three types according to their assembled structure, are characterized by their nontoxicity, biodegradability, and flexibility for clinical use, and can be mainly categorized based on their controlled release, transmucosal delivery, and transdermal delivery properties for anticancer therapy. This review covers the recent progress on the applications of LP–Gel hybrids for anticancer therapy.

show abstract